[罕见病协同效应与伙伴关系的发展：一个科学合作基金会的模式] - Suppr

Suppr

超能文献

[Development of synergies and partnerships on rare diseases: model of a scientific cooperation foundation].

作者信息

Lévy Nicolas

机构信息

Hôpital Broussais, GIS-institut des maladies rares, plate-forme maladies rares, 75014 Paris, France.

出版信息

Presse Med. 2012 May;41 Suppl 1:S23-5. doi: 10.1016/j.lpm.2012.02.029. Epub 2012 Apr 6.

DOI:10.1016/j.lpm.2012.02.029

PMID:22483766

Abstract

摘要

相似文献

[Development of synergies and partnerships on rare diseases: model of a scientific cooperation foundation].

Presse Med. 2012 May;41 Suppl 1:S23-5. doi: 10.1016/j.lpm.2012.02.029. Epub 2012 Apr 6.

Alzheimer's disease public-private partnerships: A landscape of the global nonprofit community.

Alzheimers Dement. 2013 Jul;9(4):466-71. doi: 10.1016/j.jalz.2013.05.1761.

[Interest in partnerships around the Mediterranean basin for rare diseases].

Presse Med. 2012 May;41 Suppl 1:S51-4. doi: 10.1016/j.lpm.2012.02.033. Epub 2012 Mar 28.

[Mediterranean region debate-what are the existing partnerships? What are the ones missing?].

Med Sci (Paris). 2014 Apr;30 Spe(1):40-6. doi: 10.1051/medsci/201430s110. Epub 2014 Apr 14.

Europe's innovation hub finally KICs off.

Nature. 2011 Feb 24;470(7335):450. doi: 10.1038/470450a.

Academia-pharma partnerships for novel drug discovery: essential or nice to have?

Expert Opin Drug Discov. 2017 Jun;12(6):537-540. doi: 10.1080/17460441.2017.1318124. Epub 2017 Apr 17.

Funding bodies should foster partnerships between industry and academia.

Nat Rev Cancer. 2021 Feb;21(2):65-66. doi: 10.1038/s41568-020-00326-w.

The CNCCS, a benchmark Italian consortium for bioeconomy and an opportunity for the Istituto Superiore di Sanità.

Ann Ist Super Sanita. 2012;48(2):115-6. doi: 10.4415/ANN_12_02_01.

Allocation of control rights and cooperation efficiency in public-private partnerships: theory and evidence from the Chinese pharmaceutical industry.

Int J Health Care Finance Econ. 2009 Jun;9(2):169-82. doi: 10.1007/s10754-009-9063-5. Epub 2009 Apr 10.

A transformative program, ahead of its time.

Nurs Outlook. 2014 Nov-Dec;62(6):482-90. doi: 10.1016/j.outlook.2014.09.004. Epub 2014 Oct 23.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

[Development of synergies and partnerships on rare diseases: model of a scientific cooperation foundation].

Presse Med. 2012 May;41 Suppl 1:S23-5. doi: 10.1016/j.lpm.2012.02.029. Epub 2012 Apr 6.

Alzheimer's disease public-private partnerships: A landscape of the global nonprofit community.

Alzheimers Dement. 2013 Jul;9(4):466-71. doi: 10.1016/j.jalz.2013.05.1761.

[Interest in partnerships around the Mediterranean basin for rare diseases].

Presse Med. 2012 May;41 Suppl 1:S51-4. doi: 10.1016/j.lpm.2012.02.033. Epub 2012 Mar 28.

[Mediterranean region debate-what are the existing partnerships? What are the ones missing?].

Med Sci (Paris). 2014 Apr;30 Spe(1):40-6. doi: 10.1051/medsci/201430s110. Epub 2014 Apr 14.

Europe's innovation hub finally KICs off.

Nature. 2011 Feb 24;470(7335):450. doi: 10.1038/470450a.

Academia-pharma partnerships for novel drug discovery: essential or nice to have?

Expert Opin Drug Discov. 2017 Jun;12(6):537-540. doi: 10.1080/17460441.2017.1318124. Epub 2017 Apr 17.

Funding bodies should foster partnerships between industry and academia.

Nat Rev Cancer. 2021 Feb;21(2):65-66. doi: 10.1038/s41568-020-00326-w.

The CNCCS, a benchmark Italian consortium for bioeconomy and an opportunity for the Istituto Superiore di Sanità.

Ann Ist Super Sanita. 2012;48(2):115-6. doi: 10.4415/ANN_12_02_01.

Allocation of control rights and cooperation efficiency in public-private partnerships: theory and evidence from the Chinese pharmaceutical industry.

Int J Health Care Finance Econ. 2009 Jun;9(2):169-82. doi: 10.1007/s10754-009-9063-5. Epub 2009 Apr 10.

A transformative program, ahead of its time.

Nurs Outlook. 2014 Nov-Dec;62(6):482-90. doi: 10.1016/j.outlook.2014.09.004. Epub 2014 Oct 23.